3 research outputs found
Five Stages of the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial
IDMC = Independent Data Monitoring Committee; FFS = failure-free survival; HR = hazard ratio, where 0 ≤ d ≤ c ≤ b ≤ a ≤ 5.<p><b>Copyright information:</b></p><p>Taken from "Speeding up the Evaluation of New Agents in Cancer"</p><p></p><p>JNCI Journal of the National Cancer Institute 2008;100(17):1204-1214.</p><p>Published online 3 Sep 2008</p><p>PMCID:PMC2528020.</p><p></p
Stopping guidelines on the hazard ratio scale for the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial
CI = confidence interval; HR = hazard ratio; Stop = stopping of accrual (rather than termination of follow up).<p><b>Copyright information:</b></p><p>Taken from "Speeding up the Evaluation of New Agents in Cancer"</p><p></p><p>JNCI Journal of the National Cancer Institute 2008;100(17):1204-1214.</p><p>Published online 3 Sep 2008</p><p>PMCID:PMC2528020.</p><p></p
Additional file 1: Table S1A. of A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer
Pharmacokinetics of lapatinib. Table S1B. Pharmacokinetics of foretinib. (DOCX 558 kb